financetom
Business
financetom
/
Business
/
Heidrick & Struggles International's Q2 Adjusted EPS Falls, Revenue Rises; Q3 Revenue Outlook Set
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Heidrick & Struggles International's Q2 Adjusted EPS Falls, Revenue Rises; Q3 Revenue Outlook Set
Jul 29, 2024 2:54 PM

05:44 PM EDT, 07/29/2024 (MT Newswires) -- Heidrick & Struggles International ( HSII ) reported late Monday Q2 adjusted diluted earnings of $0.67 per share, down from $0.73 a year earlier.

Three analysts polled by Capital IQ expected $0.56.

Revenue in the quarter ended June 30 rose to $282.9 million from $273.8 million a year earlier.

Three analysts surveyed by Capital IQ expected $265.7 million.

The company expects Q3 revenue of $260 million to $280 million. Three analysts surveyed by Capital IQ expect $258.6 million.

The company maintained its quarterly dividend at $0.15 a share, payable Aug. 22 to shareholders of record Aug. 9.

Price: 36.30, Change: +0.52, Percent Change: +1.45

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Thales sees more potential exports for SAMP/T air defences after Denmark win
Thales sees more potential exports for SAMP/T air defences after Denmark win
Sep 15, 2025
PARIS, Sept 15 (Reuters) - France's Thales and its partners are talking to several European and non-European countries about more potential deals after Denmark selected the Franco-Italian SAMP/T missile defence system, a senior Thales executive said. Air defence is clearly becoming a priority across Europe, not only the eastern part, Herve Dammann, Executive Vice-President for Land and Air Systems told...
Ocugen Licenses Korean Rights to Gene Therapy OCU400 in $7.5 Million Deal With Kwangdong
Ocugen Licenses Korean Rights to Gene Therapy OCU400 in $7.5 Million Deal With Kwangdong
Sep 15, 2025
07:17 AM EDT, 09/15/2025 (MT Newswires) -- Ocugen ( OCGN ) said Monday it has signed an exclusive licensing agreement with Kwangdong Pharmaceutical for the rights to commercialize its experimental gene therapy, OCU400, for the treatment of retinitis pigmentosa in South Korea. Under the deal, Ocugen ( OCGN ) said it will receive up to $7.5 million in upfront and...
Novartis signs up to $5.7 billion licensing deal with Monte Rosa Therapeutics
Novartis signs up to $5.7 billion licensing deal with Monte Rosa Therapeutics
Sep 15, 2025
(Reuters) - Swiss drugmaker Novartis and drug developer Monte Rosa Therapeutics ( GLUE ) signed a licensing deal worth up to $5.7 billion on Monday to develop drugs for immune-mediated diseases. Under the agreement, Monte Rosa Therapeutics ( GLUE ) will receive an upfront payment of $120 million and could earn up to $5.7 billion in total, including milestone payments...
Market Chatter: Apollo, Silver Point Capital Lead $900 Million Loan to Vantage Specialty Chemicals
Market Chatter: Apollo, Silver Point Capital Lead $900 Million Loan to Vantage Specialty Chemicals
Sep 15, 2025
07:16 AM EDT, 09/15/2025 (MT Newswires) -- Apollo Global Management ( APO ) and Silver Point Capital led a nearly $900 million direct loan to Vantage Specialty Chemicals to replace its current bank-arranged financing, Bloomberg News reported Friday, citing people with knowledge of the matter. Oak Hill Advisors also assisted with the funding, the news outlet reported, citing one of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved